- Home
- LANV vs NTHI Comparison
LANV vs NTHI Comparison
Compare LANV & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LANV | NTHI |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.4M | 178.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LANV | NTHI |
|---|---|---|
| Price | $1.60 | $5.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 54.2K | 28.0K |
| Earning Date | 04-29-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $3.20 |
| 52 Week High | $2.69 | $15.50 |
Technical Indicators
Market Signals| Indicator | LANV | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 24.97 |
| Support Level | $1.40 | $5.25 |
| Resistance Level | $2.33 | $5.82 |
| Average True Range (ATR) | 0.25 | 0.70 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 35.90 | 5.97 |
Price Performance
Historical ComparisonAbout LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).